- Forbes•2 years ago
While the Ebola virus has created an enormous amount of stress, anxiety and political debate globally, it is important to move the trajectory to areas that are equally important and not so visibly covered by current press. What are predictions on the new Ebola cases and the associated burden in 2015
- Zacks Small Cap Research•2 years ago
Corgenix Medical (CONX) reported financial results for the fiscal third quarter ending March 31, 2013. Revenue was somewhat disappointing and below our estimate, with international sales remaining relatively weak. North American sales were roughly flat and benefitted from a very strong showing in contract R&D revenue. The relative softness in the top line did not translate into equally weak net income, however, as continued focus on expense management and absorption of much of R&D expense by grant revenue helped CONX turn in another profitable quarter. And while management's outlook for the international business is tepid over at least the next couple of quarters (until certain catalysts are expected to make a positive impact), the company continues to expect fiscal 2014 (ending June 30) to set another record in revenue and income. We now model full-year revenue growth of 8%. Importantly, gross margins continue to improve - partly a result of higher sales volumes and partly from improvement to manufacturing processes. GM have widened from 42.4% in fiscal 2012 to 44.8% in 2013 (with some of this improvement also likely a result of significantly greater services-related revenue) and a 46.9% average through the first six nine months of fiscal 2014. Management noted on the call that they expect further improvement in GM.
CORGENIX MED CORPOther OTC
|Day's Range||0.00 - 0.00|
|Avg Vol (3m)||N/A|
As of 10:28 AM EDT. Market closed.